O	0	5	First
O	5	6	-
O	6	10	line
B-intervention	11	22	gemcitabine
O	23	29	versus
B-control	30	40	epirubicin
O	41	43	in
O	44	58	postmenopausal
O	59	64	women
O	65	69	aged
O	70	72	60
O	73	75	or
O	76	81	older
O	82	86	with
O	87	97	metastatic
O	98	104	breast
O	105	111	cancer
O	111	112	:
O	113	114	a
O	115	126	multicenter
O	126	127	,
O	128	138	randomized
O	138	139	,
O	140	145	phase
O	146	149	III
O	150	155	study
O	155	156	.

O	157	161	This
O	162	172	randomized
O	172	173	,
O	174	179	phase
O	180	183	III
O	184	189	study
O	190	198	compared
O	199	202	the
O	203	211	efficacy
O	212	215	and
O	216	222	safety
O	223	225	of
O	226	231	first
O	231	232	-
O	232	236	line
O	237	248	gemcitabine
O	249	255	versus
O	256	266	epirubicin
O	267	269	in
O	270	273	the
O	274	283	treatment
O	284	286	of
O	287	301	postmenopausal
O	302	307	women
O	308	312	with
O	313	323	metastatic
O	324	330	breast
O	331	337	cancer
O	338	339	(
O	339	342	MBC
O	342	343	)
O	343	344	.

O	345	353	Patients
O	354	358	aged
B-age	359	360	>
I-age	361	363	or
I-age	364	365	=
I-age	366	368	60
I-age	369	374	years
O	375	376	(
O	376	382	median
O	383	385	68
O	386	391	years
O	391	392	)
B-eligibility	393	397	with
I-eligibility	398	408	clinically
I-eligibility	409	419	measurable
I-eligibility	420	423	MBC
O	424	432	received
O	433	439	either
O	440	451	gemcitabine
O	452	456	1200
O	457	459	mg
O	459	460	/
O	460	461	m
O	461	462	(
O	462	463	2
O	463	464	)
O	465	467	or
O	468	478	epirubicin
O	479	481	35
O	482	484	mg
O	484	485	/
O	485	486	m
O	486	487	(
O	487	488	2
O	488	489	)
O	490	492	on
O	493	497	days
O	498	499	1
O	499	500	,
O	501	502	8
O	502	503	,
O	504	507	and
O	508	510	15
O	511	513	of
O	514	515	a
O	516	518	28
O	518	519	-
O	519	522	day
O	523	528	cycle
O	528	529	.

O	530	532	Of
B-total-participants	533	536	410
O	537	545	patients
O	546	553	entered
O	553	554	,
B-total-participants	555	558	397
O	559	560	(
B-intervention-participants	560	563	198
O	564	575	gemcitabine
O	576	579	and
B-control-participants	580	583	199
O	584	594	epirubicin
O	594	595	)
O	596	600	were
O	601	611	randomized
O	612	615	and
O	616	625	qualified
O	626	629	for
O	630	633	the
O	634	638	time
O	639	641	to
O	642	653	progressive
O	654	661	disease
O	662	663	(
O	663	666	TTP
O	666	667	)
O	668	671	and
O	672	680	survival
O	681	689	analyses
O	689	690	.

O	691	696	Total
O	697	703	cycles
O	704	716	administered
O	717	719	in
O	720	723	185
O	724	735	gemcitabine
O	736	739	and
O	740	743	192
O	744	754	epirubicin
O	755	763	patients
O	763	764	,
O	765	777	respectively
O	777	778	,
O	779	783	were
O	784	787	699
O	788	789	(
O	789	793	mean
O	794	795	3
O	795	796	.
O	796	797	5
O	797	798	,
O	799	804	range
O	805	806	0
O	806	807	-
O	807	809	12
O	809	810	)
O	811	814	and
O	815	818	917
O	819	820	(
O	820	824	mean
O	825	826	4
O	826	827	.
O	827	828	6
O	828	829	,
O	830	835	range
O	836	837	0
O	837	838	-
O	838	840	10
O	840	841	)
O	841	842	.

O	843	853	Epirubicin
O	854	866	demonstrated
O	867	880	statistically
O	881	892	significant
O	893	904	superiority
O	905	907	in
B-outcome	908	911	TTP
O	912	913	(
B-cv-cont-median	913	914	6
I-cv-cont-median	914	915	.
I-cv-cont-median	915	916	1
O	917	920	and
B-iv-cont-median	921	922	3
I-iv-cont-median	922	923	.
I-iv-cont-median	923	924	4
I-iv-cont-median	925	931	months
O	931	932	,
O	933	934	P
O	934	935	=
O	935	936	0
O	936	937	.
O	937	941	0001
O	941	942	)
O	942	943	,
B-outcome	944	951	overall
I-outcome	952	960	survival
O	961	962	(
B-cv-cont-median	962	964	19
I-cv-cont-median	964	965	.
I-cv-cont-median	965	966	1
O	967	970	and
B-iv-cont-median	971	973	11
I-iv-cont-median	973	974	.
I-iv-cont-median	974	975	8
I-iv-cont-median	976	982	months
O	982	983	,
O	984	985	P
O	985	986	=
O	986	987	0
O	987	988	.
O	988	992	0004
O	992	993	)
O	993	994	,
O	995	998	and
O	999	1012	independently
O	1013	1021	assessed
B-outcome	1022	1030	response
I-outcome	1031	1035	rate
O	1036	1037	(
B-cv-bin-percent	1037	1039	40
I-cv-bin-percent	1039	1040	.
I-cv-bin-percent	1040	1041	3
I-cv-bin-percent	1041	1042	%
O	1043	1046	and
B-iv-bin-percent	1047	1049	16
I-iv-bin-percent	1049	1050	.
I-iv-bin-percent	1050	1051	4
I-iv-bin-percent	1051	1052	%
O	1053	1055	in
B-control-participants	1056	1059	186
O	1060	1063	and
B-intervention-participants	1064	1067	183
O	1068	1077	evaluable
O	1078	1086	patients
O	1086	1087	,
O	1088	1089	P
O	1090	1091	<
O	1091	1092	0
O	1092	1093	.
O	1093	1096	001
O	1096	1097	)
O	1097	1098	.

O	1099	1102	For
O	1103	1114	gemcitabine
O	1115	1116	(
O	1116	1117	n
O	1117	1118	=
B-intervention-participants	1118	1121	190
O	1121	1122	)
O	1123	1126	and
O	1127	1137	epirubicin
O	1138	1139	(
O	1139	1140	n
O	1140	1141	=
B-control-participants	1141	1144	192
O	1144	1145	)
O	1145	1146	,
O	1147	1159	respectively
O	1159	1160	,
O	1161	1167	common
O	1168	1171	WHO
B-outcome	1172	1177	grade
I-outcome	1178	1179	3
I-outcome	1179	1180	/
I-outcome	1180	1181	4
I-outcome	1182	1192	toxicities
O	1193	1197	were
B-outcome	1198	1209	neutropenia
O	1210	1211	(
B-iv-bin-percent	1211	1213	25
I-iv-bin-percent	1213	1214	.
I-iv-bin-percent	1214	1215	3
I-iv-bin-percent	1215	1216	%
O	1217	1220	and
B-cv-bin-percent	1221	1223	17
I-cv-bin-percent	1223	1224	.
I-cv-bin-percent	1224	1225	9
I-cv-bin-percent	1225	1226	%
O	1226	1227	)
O	1228	1231	and
B-outcome	1232	1242	leukopenia
O	1243	1244	(
B-iv-bin-percent	1244	1246	14
I-iv-bin-percent	1246	1247	.
I-iv-bin-percent	1247	1248	3
I-iv-bin-percent	1248	1249	%
O	1250	1253	and
B-cv-bin-percent	1254	1256	19
I-cv-bin-percent	1256	1257	.
I-cv-bin-percent	1257	1258	3
I-cv-bin-percent	1258	1259	%
O	1259	1260	)
O	1260	1261	.

O	1262	1264	Of
O	1265	1268	the
O	1269	1271	28
O	1272	1274	on
O	1274	1275	-
O	1275	1280	study
B-outcome	1281	1287	deaths
O	1288	1289	(
B-iv-bin-abs	1289	1291	17
O	1292	1303	gemcitabine
O	1303	1304	,
B-cv-bin-abs	1305	1307	11
O	1308	1318	epirubicin
O	1318	1319	)
O	1319	1320	,
O	1321	1326	three
O	1327	1331	were
O	1332	1342	considered
O	1343	1351	possibly
O	1352	1354	or
O	1355	1363	probably
O	1364	1371	related
O	1372	1374	to
O	1375	1384	treatment
O	1385	1386	(
O	1386	1397	gemcitabine
O	1397	1398	)
O	1398	1399	.

O	1400	1414	Postmenopausal
O	1415	1420	women
O	1421	1422	>
O	1423	1425	or
O	1426	1427	=
O	1427	1429	60
O	1430	1435	years
O	1436	1438	of
O	1439	1442	age
O	1443	1447	with
O	1448	1451	MBC
O	1452	1460	tolerate
O	1461	1473	chemotherapy
O	1474	1478	well
O	1478	1479	.

O	1480	1482	In
O	1483	1487	this
O	1488	1493	study
O	1493	1494	,
O	1495	1505	epirubicin
O	1506	1509	was
O	1510	1518	superior
O	1519	1521	to
O	1522	1533	gemcitabine
O	1534	1536	in
O	1537	1540	the
O	1541	1550	treatment
O	1551	1553	of
O	1554	1557	MBC
O	1558	1560	in
O	1561	1566	women
O	1567	1570	age
O	1571	1572	>
O	1573	1575	or
O	1576	1577	=
O	1577	1579	60
O	1579	1580	,
O	1581	1591	confirming
O	1592	1596	that
O	1597	1611	anthracyclines
O	1612	1618	remain
O	1619	1628	important
O	1629	1634	drugs
O	1635	1638	for
O	1639	1644	first
O	1644	1645	-
O	1645	1649	line
O	1650	1659	treatment
O	1660	1662	of
O	1663	1666	MBC
O	1666	1667	.
